Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vectivbio Holding Ag (NQ: VECT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vectivbio Holding Ag

< Previous 1 2 3 Next >
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
From VectivBio AG
Via GlobeNewswire
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
From Ironwood Pharmaceuticals, Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About VectivBio Holding
Via Benzinga
Piper Sandler Maintains Overweight Rating for VectivBio Holding: Here's What You Need To Know
Via Benzinga
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned. 
Via The Motley Fool
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
From Kahn Swick & Foti, LLC
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023
Via Benzinga
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
Investors indicated approval of the company's upcoming $1 billion asset purchase. 
Via The Motley Fool
Ironwood Scoops Up Gastrointestinal Diseases Player For $1B
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has agreed to acquire VectivBio Holding AG (NASDAQ: VECT) for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of... 
Via Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share. 
Via Benzinga
Why Shares of VectivBio Holding Are Up Today
A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock. 
Via The Motley Fool
Merger Monday
This morning, Chevron announced a deal to acquire PDC Energy for $72 per share in stock. 
Via Talk Markets
Why VectivBio Shares Are Surging Monday
VectivBio Holding AG (NASDAQ: VECT) shares are trading higher Monday after GI-focused healthcare company Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) agreed to 
Via Benzinga
US Stocks Mixed; Nordic American Tankers Posts Upbeat Results
U.S. stocks traded mixed this morning, with the Dow Jones trading slightly lower on Monday. Following the market opening Monday, the Dow traded down 0.01% to 33,422.94 while the NASDAQ rose 0.09% to... 
Via Benzinga
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
Both companies are working on treatments for gastrointestinal diseases. 
Via Investor's Business Daily
Benzinga Pro's Top 5 Stocks To Watch For Monday, May 22, 2023: MU, RKT, DLTR, LDOS, IRWD
Micron Technology (MU) - Shares were down about 4% Monday morning following a report the Chinese government found cybersecurity issues related to Micron's products. Chinese officials have asked 
Via Benzinga
VECT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VectivBio Holding AG Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
VectivBio Publishes Invitation to the Annual General Meeting
From VectivBio AG
Via GlobeNewswire
VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
From VectivBio AG
Via GlobeNewswire
VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023
Management to Host Conference Call Wednesday, April 19, 2023, at 8.00 a.m. ET 
From VectivBio AG
Via GlobeNewswire
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
Single-dose study to assess pharmacokinetics, pharmacological activity, safety and tolerability in healthy Japanese men and women 
From VectivBio AG
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022
Via Benzinga
VectivBio Announces Results of Extraordinary General Meeting
-Wouter Joustra Elected to the Board of Directors 
From VectivBio AG
Via GlobeNewswire
VectivBio Publishes Invitation to the Extraordinary General Meeting of Shareholders
From VectivBio AG
Via GlobeNewswire
VectivBio to Present at the 2022 Jefferies London Healthcare Conference
From VectivBio AG
Via GlobeNewswire
VectivBio Announces Completion of Enrollment for Colon-In-Continuity (CIC) Cohort of STARS Pivotal Phase 3 Study Investigating Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF)
From VectivBio AG
Via GlobeNewswire
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares
From VectivBio AG
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.